These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 11840264)

  • 41. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
    Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
    J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.
    Postema EJ; Oyen WJ; Boerman OC; Corstens FH
    J Nucl Med; 2003 May; 44(5):853. PubMed ID: 12732690
    [No Abstract]   [Full Text] [Related]  

  • 43. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.
    Illidge T; Honeychurch J; Vandersteen A; Cragg M
    Cancer Biother Radiopharm; 2000 Dec; 15(6):581-91. PubMed ID: 11190490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
    Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
    Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
    Sugyo A; Tsuji AB; Sudo H; Okada M; Koizumi M; Satoh H; Kurosawa G; Kurosawa Y; Saga T
    PLoS One; 2015; 10(4):e0123761. PubMed ID: 25893775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice.
    Vallera DA; Elson M; Brechbiel MW; Dusenbery KE; Burns LJ; Skubitz KM; Jaszcz WB; Ramsay NK; Panoskaltsis-Mortari A; Kuroki DW; Wagner JE; Kersey JH
    Cancer Biother Radiopharm; 2003 Apr; 18(2):133-45. PubMed ID: 12804039
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.
    Watanabe N; Oriuchi N; Endo K; Inoue T; Kuroki M; Matsuoka Y; Tanada S; Murata H; Kim EE; Sasaki Y
    J Nucl Med; 2000 Feb; 41(2):337-44. PubMed ID: 10688120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.
    Orozco JJ; Balkin ER; Gooley TA; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Hylarides MD; Shadman M; Green DJ; Gopal AK; Press OW; Pagel JM
    PLoS One; 2014; 9(12):e113601. PubMed ID: 25460570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody.
    Aung W; Tsuji AB; Sudo H; Sugyo A; Ukai Y; Kouda K; Kurosawa Y; Furukawa T; Saga T
    Oncotarget; 2016 Jun; 7(25):38835-38844. PubMed ID: 27246980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
    Weiden PL; Breitz HB
    Crit Rev Oncol Hematol; 2001 Oct; 40(1):37-51. PubMed ID: 11578915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
    Stein R; Chen S; Haim S; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2636-41. PubMed ID: 9406718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts.
    Heryanto YD; Hanaoka H; Nakajima T; Yamaguchi A; Tsushima Y
    Ann Nucl Med; 2017 Nov; 31(9):669-677. PubMed ID: 28741052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
    Salaun PY; Bodet-Milin C; Frampas E; Oudoux A; Saï-Maurel C; Faivre-Chauvet A; Barbet J; Paris F; Kraeber-Bodéré F
    Cancer; 2010 Feb; 116(4 Suppl):1053-8. PubMed ID: 20127950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
    Bischof Delaloye A
    Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma.
    Leonard JP; Siegel JA; Goldsmith SJ
    Cancer Invest; 2003 Apr; 21(2):241-52. PubMed ID: 12743990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
    Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
    J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer Xenografts.
    Fujiwara K; Koyama K; Suga K; Ikemura M; Saito Y; Hino A; Iwanari H; Kusano-Arai O; Mitsui K; Kasahara H; Fukayama M; Kodama T; Hamakubo T; Momose T
    PLoS One; 2015; 10(5):e0125468. PubMed ID: 26017283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.